Pliant Therapeutics Inc Cash Flow Conversion Efficiency
Pliant Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has a cash flow conversion efficiency ratio of -0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.80 Million) by net assets ($146.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pliant Therapeutics Inc (2017–2025)
Cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2025. This chart illustrates how Pliant Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Pliant Therapeutics Inc for real-time trading data and today's change.
Pliant Therapeutics Inc Cash Flow Conversion Ratio Explained
Pliant Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pliant Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pliant Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Pliant Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Danang Rubber JSC
VN:DRC
|
0.052x |
|
Yatra Online Inc
NASDAQ:YTRA
|
-0.051x |
|
Sachem Capital Corp
NYSE MKT:SACH
|
-0.017x |
|
Star Media Group Bhd
KLSE:6084
|
-0.014x |
|
LTR Pharma Ltd
AU:LTP
|
-0.089x |
|
Bigbloc Construction Limited
NSE:BIGBLOC
|
0.063x |
|
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
|
-0.096x |
|
Drilling Tools International Corp.
NASDAQ:DTI
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Pliant Therapeutics Inc from 2017 to 2025. Review free cash flow generation of Pliant Therapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $181.21 Million | $-128.34 Million | -0.708x | -38.49% |
| 2024-12-31 | $304.08 Million | $-155.50 Million | -0.511x | -108.13% |
| 2023-12-31 | $473.58 Million | $-116.36 Million | -0.246x | +18.64% |
| 2022-12-31 | $313.34 Million | $-94.63 Million | -0.302x | +20.31% |
| 2021-12-31 | $199.06 Million | $-75.44 Million | -0.379x | -187.84% |
| 2020-12-31 | $283.06 Million | $-37.27 Million | -0.132x | -102.08% |
| 2019-12-31 | $-435.00K | $-2.75 Million | 6.322x | -80.32% |
| 2018-12-31 | $-882.00K | $-28.33 Million | 32.118x | +738.60% |
| 2017-12-31 | $3.37 Million | $-16.92 Million | -5.029x | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more